PACE4-Based Molecular Targeting of Prostate Cancer Using an Engineered (64)Cu-Radiolabeled Peptide Inhibitor()()

The potential of PACE4 as a pharmacological target in prostate cancer has been demonstrated as this proprotein convertase is strongly overexpressed in human prostate cancer tissues and its inhibition, using molecular or pharmacological approaches, results in reduced cell proliferation and tumor prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Couture, Frédéric, Levesque, Christine, Dumulon-Perreault, Véronique, Ait-Mohand, Samia, D’Anjou, François, Day, Robert, Guérin, Brigitte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235008/
https://www.ncbi.nlm.nih.gov/pubmed/25220591
http://dx.doi.org/10.1016/j.neo.2014.07.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235008/
https://www.ncbi.nlm.nih.gov/pubmed/25220591
http://dx.doi.org/10.1016/j.neo.2014.07.010

Ejemplares similares